These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1341 related articles for article (PubMed ID: 28735109)
1. Design and rationale for a real-world observational cohort of patients with nonalcoholic fatty liver disease: The TARGET-NASH study. Barritt AS; Gitlin N; Klein S; Lok AS; Loomba R; Malahias L; Powell M; Vos MB; Weiss LM; Cusi K; Neuschwander-Tetri BA; Sanyal A Contemp Clin Trials; 2017 Oct; 61():33-38. PubMed ID: 28735109 [TBL] [Abstract][Full Text] [Related]
2. Similarities and differences between pediatric and adult nonalcoholic fatty liver disease. Crespo M; Lappe S; Feldstein AE; Alkhouri N Metabolism; 2016 Aug; 65(8):1161-71. PubMed ID: 26961580 [TBL] [Abstract][Full Text] [Related]
3. Noninvasive evaluation of nonalcoholic fatty liver disease: Current evidence and practice. Zhou JH; Cai JJ; She ZG; Li HL World J Gastroenterol; 2019 Mar; 25(11):1307-1326. PubMed ID: 30918425 [TBL] [Abstract][Full Text] [Related]
4. Bioinformatics analysis reveals novel core genes associated with nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Feng G; Li XP; Niu CY; Liu ML; Yan QQ; Fan LP; Li Y; Zhang KL; Gao J; Qian MR; He N; Mi M Gene; 2020 Jun; 742():144549. PubMed ID: 32184169 [TBL] [Abstract][Full Text] [Related]
6. Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH. Traussnigg S; Kienbacher C; Halilbasic E; Rechling C; Kazemi-Shirazi L; Hofer H; Munda P; Trauner M Dig Dis; 2015; 33(4):598-607. PubMed ID: 26159280 [TBL] [Abstract][Full Text] [Related]
7. [Overview of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis Management]. Kim SK; Kim KI; Kim SR Yakugaku Zasshi; 2019; 139(9):1147-1153. PubMed ID: 31474630 [TBL] [Abstract][Full Text] [Related]
8. [An interpretation of the AASLD practice guideline on the diagnosis and management of nonalcoholic fatty liver disease in 2017]. Nan YM; Fu N; Li WC; Kong LL; Yuan XW; Zhang SY; Liu LD; Lu Y; Cui LY Zhonghua Gan Zang Bing Za Zhi; 2017 Sep; 25(9):687-694. PubMed ID: 29108191 [TBL] [Abstract][Full Text] [Related]
9. Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Takahashi Y; Fukusato T World J Gastroenterol; 2014 Nov; 20(42):15539-48. PubMed ID: 25400438 [TBL] [Abstract][Full Text] [Related]
10. [An Overview of NAFLD/NASH in Japan]. Kim SR; Kim KI Yakugaku Zasshi; 2016; 136(4):565-72. PubMed ID: 27040340 [TBL] [Abstract][Full Text] [Related]
11. Features of nonalcoholic steatohepatitis in severely obese children and adolescents undergoing sleeve gastrectomy. Alqahtani A; Elahmedi M; Alswat K; Arafah M; Fagih M; Lee J Surg Obes Relat Dis; 2017 Sep; 13(9):1599-1609. PubMed ID: 28600116 [TBL] [Abstract][Full Text] [Related]
12. Recommendations for Diagnosis, Referral for Liver Biopsy, and Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Spengler EK; Loomba R Mayo Clin Proc; 2015 Sep; 90(9):1233-46. PubMed ID: 26219858 [TBL] [Abstract][Full Text] [Related]
14. Nonalcoholic-Fatty-Liver-Disease and Nonalcoholic Steatohepatitis: Successful Development of Pharmacological Treatment Will Depend on Translational Research. Gottlieb A; Mosthael W; Sowa JP; Canbay A Digestion; 2019; 100(2):79-85. PubMed ID: 30537758 [TBL] [Abstract][Full Text] [Related]
15. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Takahashi Y; Sugimoto K; Inui H; Fukusato T World J Gastroenterol; 2015 Apr; 21(13):3777-85. PubMed ID: 25852263 [TBL] [Abstract][Full Text] [Related]
16. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. McPherson S; Hardy T; Henderson E; Burt AD; Day CP; Anstee QM J Hepatol; 2015 May; 62(5):1148-55. PubMed ID: 25477264 [TBL] [Abstract][Full Text] [Related]
17. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Watanabe S; Hashimoto E; Ikejima K; Uto H; Ono M; Sumida Y; Seike M; Takei Y; Takehara T; Tokushige K; Nakajima A; Yoneda M; Saibara T; Shiota G; Sakaida I; Nakamuta M; Mizuta T; Tsubouchi H; Sugano K; Shimosegawa T; ; J Gastroenterol; 2015 Apr; 50(4):364-77. PubMed ID: 25708290 [TBL] [Abstract][Full Text] [Related]
18. Lifestyle intervention for morbid obesity: effects on liver steatosis, inflammation, and fibrosis. Hohenester S; Christiansen S; Nagel J; Wimmer R; Artmann R; Denk G; Bischoff M; Bischoff G; Rust C Am J Physiol Gastrointest Liver Physiol; 2018 Sep; 315(3):G329-G338. PubMed ID: 29878845 [TBL] [Abstract][Full Text] [Related]
19. Epidemiology and Natural History of Nonalcoholic Fatty Liver Disease. Satapathy SK; Sanyal AJ Semin Liver Dis; 2015 Aug; 35(3):221-35. PubMed ID: 26378640 [TBL] [Abstract][Full Text] [Related]
20. The diagnosis and treatment of non-alcoholic fatty liver disease. Altinbas A; Sowa JP; Hasenberg T; Canbay A Minerva Gastroenterol Dietol; 2015 Sep; 61(3):159-69. PubMed ID: 26080905 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]